We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+11.75%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$1.02B
AUM Growth
+$38.1M
Cap. Flow
+$21.6M
Cap. Flow %
2.1%
Top 10 Hldgs %
51.66%
Holding
52
New
9
Increased
9
Reduced
24
Closed
1

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$28.1M
2
MRUS
Merus
MRUS
+$27.9M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$25.3M
4
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$19.7M
5
GLMD icon
Galmed Pharmaceuticals
GLMD
+$14.2M

Top Sells

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$87.2M
2
ARQL
Arqule Inc
ARQL
+$34.3M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$19.6M
4
ARRY
Array Biopharma Inc
ARRY
+$6.21M
5
RCUS icon
Arcus Biosciences
RCUS
+$4.86M

Sector Composition

Rank Sector Weight
1 Healthcare 83.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCXI
1
DELISTED
ChemoCentryx, Inc.
CCXI
$92.6M 9.04%
7,034,346
-166,970
-2% -$2M
MRUS
2
DELISTED
Merus
MRUS
$89.1M 8.7%
3,914,913
+1,495,470
+62% +$27.9M
ARRY
3
DELISTED
Array Biopharma Inc
ARRY
$78.4M 7.65%
4,672,195
-390,573
-8% -$6.21M
CYTK icon
4
Cytokinetics
CYTK
$10.9B
$46.1M 4.5%
5,550,890
-170,998
-3% -$1.42M
ARQL
5
DELISTED
Arqule Inc
ARQL
$41.2M 4.02%
7,447,912
-8,989,000
-55% -$34.3M
BPMC
6
DELISTED
Blueprint Medicines
BPMC
$41.1M 4.01%
646,811
-8,800
-1% -$700K
KURA icon
7
Kura Oncology
KURA
$826M
$37.4M 3.65%
2,057,346
+703,500
+52% +$11.9M
MRTX
8
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$36.7M 3.58%
+745,000
New +$28.1M
CTIC
9
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$34.5M 3.37%
6,929,690
– –
XNCR icon
10
Xencor
XNCR
$1.59B
$32.2M 3.14%
869,645
-32,355
-4% -$1.11M
XOMA
11
DELISTED
Xoma
XOMA
$31.4M 3.06%
1,502,800
– –
CNCE
12
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$30.6M 2.98%
1,817,138
-114,985
-6% -$2.23M
INFI
13
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$29.1M 2.84%
15,232,268
+5,465,760
+56% +$11M
PVLA
14
Palvella Therapeutics
PVLA
$2.15B
$27.1M 2.65%
66,835
+21,928
+49% +$10.4M
ANAB icon
15
AnaptysBio
ANAB
$1.63B
$23.8M 2.32%
335,265
-50,800
-13% -$4.26M
IONS icon
16
Ionis Pharmaceuticals
IONS
$8.85B
$23.8M 2.32%
+570,000
New +$25.3M
BLRX
17
BioLineRX
BLRX
$11.7M
$23.5M 2.3%
43,326
– –
FWP
18
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$23.1M 2.26%
1,214,775
+535,473
+79% +$9.24M
GLMD icon
19
Galmed Pharmaceuticals
GLMD
$4.95M
$21M 2.05%
+9,786
New +$14.2M
CRVS icon
20
Corvus Pharmaceuticals
CRVS
$1.11B
$20.8M 2.03%
1,890,507
-63,747
-3% -$712K
IMDZ
21
DELISTED
Immune Design Corp.
IMDZ
$18.9M 1.85%
4,158,353
+52,153
+1% +$208K
FPRX
22
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$17.9M 1.74%
+1,129,761
New +$19.7M
VSTM icon
23
Verastem
VSTM
$536M
$15.4M 1.51%
186,863
-41,220
-18% -$2.52M
SPRO icon
24
Spero Therapeutics
SPRO
$69.5M
$15.4M 1.5%
1,048,958
– –
LITS
25
Lite Strategy Inc
LITS
$33.6M
$12.1M 1.18%
+154,015
New +$9.44M
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2018 Portfolio in Review

As of Q2 2018, BVF Inc held 52 positions worth $1.02B, up 3.9% from $986M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

BVF Inc's Q2 2018 filing shows 9 new, 9 increased, 24 reduced and 1 closed positions. Its largest new stake was Mirati Therapeutics, Inc. Common Stock: 745,000 shares worth $36.7M. The largest sale was Ironwood Pharmaceuticals, an estimated $87.2M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier.

  • BVF Inc's largest Q2 2018 buy was Mirati Therapeutics, Inc. Common Stock: 745,000 shares worth $36.7M.
  • BVF Inc added most to Merus in Q2 2018, an estimated $27.9M increase.
  • BVF Inc's biggest Q2 2018 reduction was Ironwood Pharmaceuticals, cutting an estimated $87.2M.
  • BVF Inc fully exited Orexigen Therapeutics, Inc. in Q2 2018, selling an estimated $108K.
  • BVF Inc's ten largest holdings make up 52% of its $1.02B portfolio in Q2 2018.
  • BVF Inc opened 9 new positions and closed 1 in Q2 2018.
  • BVF Inc's portfolio value rose 3.9% quarter-over-quarter to $1.02B.

Based on BVF Inc's 13F filing for Q2 2018, filed 14 Aug 2018.